|
|
|
|
|
|
|
|
|
|
http://www.onclive.com/web-exclusives/expert-says-biomarkers-top-priority-for-immunotherapy-progress-in-ovarian-cancer
December 13, 2016
In an interview with OncLive, Maurie Markman, president of Medicine and Science, Cancer Treatment Centers of America, discussed his presentation from the recent 2016 Chemotherapy Foundation Symposium (CFS), and comments on both recent advances and remaining challenges in the treatment of ovarian cancer....
... Only time will tell. But in my opinion, that’s what I would like to see in the next year—not another story of a 500-patient randomized phase III trial that is going to take 3 to 5 years to finish, maybe, if ever, and will show that there is minimal to no impact on an important clinical outcome.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.